Relay Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, good afternoon. Saving the best for the last here. Thank you for joining. This is Debjit from Guggenheim Therapeutics team. Thank you all for joining our 3rd annual Healthcare Innovation Conference. My privilege to welcome Sanjiv Patel, President and CEO of Relay Therapeutics. Joining Sanjiv are Don Bergstrom, President of R&D, and Pete Rahmer, Chief Corporate Development Officer.
Thank you all. Thank you, Debjit, for the invite.
It is a pleasure to be here.
I do not want to insult your intelligence by asking you to do an intro.
No. Why don't we just get straight to the Q&A?
I am happy to do an intro.
No, I think anybody on this, anybody listening in probably knows enough about Relay.
Okay. Let's skip the intro.
All right. Thank you. because there is a lot happening with the company.
Yeah. I want to start on the ASH update.
Yeah. Let's talk about the data first.
We are expecting somewhere in the ballpark of 60 patients. Is that sort of a right estimate?
I think at the moment, all we're saying is that the ISSVA data that we showed back in May of this year, we showed data on the 32 patients in the dose randomization portion. Of those 32 patients, we showed safety data on all 32, and we showed efficacy data on 20, and that was because 12 of those patients hadn't yet had a scan at the data cut. At ASH, what we'll show is those 32 patients again, and we'll show now efficacy and safety data on all 32 patients. As you may remember, back in ISSVA, we showed across those three doses a 60% volumetric response rate. I think the question for investors is, how has that evolved as we go from this N of 20 to 32?
Our hope is that it stays in and around that, and that we can show some consistency to make sure that investors understand how differentiated our therapy is. Obviously, looking at the much longer follow-up on that, how the safety profile evolves, we would obviously want it to stay consistent to what we saw earlier in the year. Then we will show additional data from the dose expansion portion of the trial. There, the majority of the patients that we have enrolled in those dose escalation cohorts have been at the 400 milligrams once a day. We are not going to say today how many patients we will show there, but those patients will predominantly have had only one scan. So, the efficacy of earlier patients will only be at the 12 weeks. The goal there is to show two things. One, we want to show a very tolerable profile.
As we came out of ISSVA, the real predominant feedback from the community of treating physicians is tolerability is key. The volumetric response rate is interesting for the FDA, but what patients want is a tolerable therapy they can take for life. So, the focus of us in this, choosing the dose to go forward with in the pivotal trial, is going to be what is a dose that a patient can take forever? So what we want to show is low levels of hyperglycemia, diarrhea, rash, dermatitis. Obviously, the efficacy profile has to be differentiated, so it has to clear the bar of alpelisib in the kind of high 20s. So as long as we can do that with a tolerable safety profile, I think investors should feel very confident that we will produce a differentiated therapy that should be commercially successful.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
